This is supported by the finding that most of the studies that stratified by inflammatory markers found better efficacy in those patients who had evidence of inflammation at baseline: Nettis et al. found an effect for Minocycline in depression only in the subgroup of patients with CRP>/3 (Nettis et al., 2021). Here, CRP is linked to depressive disorder.